Novartis keeps a close eye on gene therapy with Vedere Bio buyAlready a major player in gene therapy, Novartis has swooped on US startup Vedere Bio in a $280 Share XNovartis keeps a close eye on gene therapy with Vedere Bio buyhttps://pharmaphorum.com/news/novartis-keeps-a-close-eye-on-gene-therapy-with-vedere-bio-buy/
Exact Sciences buys cancer detection company Thrive for $2.15 billionStocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK Share XExact Sciences buys cancer detection company Thrive for $2.15 billionhttps://pharmaphorum.com/news/exact-sciences-buys-early-cancer-detection-company-thrive-for-2-15-billion/
Bayer buys cell & gene therapy firm AskBio for $4 billionBayer is making clear its ambitions in cell and gene therapy with a $4 billion acquisition of US Share XBayer buys cell & gene therapy firm AskBio for $4 billionhttps://pharmaphorum.com/news/bayer-extends-reach-in-cell-gene-therapy-with-askbio-acquisition/
David Hung’s Nuvation Bio seals merger with blank cheque firm PanaceaTwo years after quietly forming cancer start-up Nuvation Bio, ex-Axovant and Medivation CEO David Hung has agreed a Share XDavid Hung’s Nuvation Bio seals merger with blank cheque firm Panaceahttps://pharmaphorum.com/news/david-hungs-nuvation-bio-seals-merger-with-blank-cheque-firm-panacea/
BMS bulks up in cardio with $13.1bn takeover deal for MyoKardiaBristol-Myers Squibb has said it will buy biotech MyoKardia in a $13.1 billion takeover that marks a step Share XBMS bulks up in cardio with $13.1bn takeover deal for MyoKardiahttps://pharmaphorum.com/news/bms-bulks-up-in-cardio-with-13-1bn-takeover-deal-for-myokardia/
Roche bulks up in inflammation with €380m Inflazome acquisitionRoche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory diseases, buying Irish biotech Share XRoche bulks up in inflammation with €380m Inflazome acquisitionhttps://pharmaphorum.com/news/roche-bulks-up-in-inflammation-with-e380m-inflazome-acquisition/
Illumina wants to bring liquid biopsy spinout Grail back in-house; reportCancer diagnosis firm Grail could be re-joining Illumina, the company it was spun out of in 2016, despite Share XIllumina wants to bring liquid biopsy spinout Grail back in-house; reporthttps://pharmaphorum.com/news/illumina-wants-to-bring-liquid-biopsy-spinout-grail-back-in-house-report/
Gilead pays $21bn for Immunomedics ahead of breast cancer trial readoutGilead has made another big oncology acquisition, paying $21 billion for US biotech Immunomedics and its potential cancer Share XGilead pays $21bn for Immunomedics ahead of breast cancer trial readouthttps://pharmaphorum.com/news/gilead-pays-21bn-for-immunomedics-ahead-of-breast-cancer-trial-readout/
Ex-Allergan CEO Saunders pops up again in ‘blank cheque’ companyBrent Saunders has been out of the limelight for a few months since departing Allergan after its takeover Share XEx-Allergan CEO Saunders pops up again in ‘blank cheque’ companyhttps://pharmaphorum.com/news/ex-allergan-ceo-saunders-pops-up-again-in-blank-cheque-company/
